- ►annals.org [PDF] SM Cadarette, JN Katz, MA Brookhart, T … - Annals of Internal Medicine, 2008 - Am Coll Physicians Background: Little information is available on the comparative ef- fectiveness
of osteoporosis pharmacotherapies. ... Objective: To compare the relative
effectiveness of osteoporosis treatments to reduce nonvertebral fracture ... Cited by 18 - Related articles - All 7 versions
ST Harris, JY Reginster, C Harley, WA … - Bone, 2009 - Elsevier This large study included women ≥ 45 years old, newly prescribed monthly oral
ibandronate or weekly oral alendronate or risedronate, and without malignancy or
Paget's disease of bone. The primary analysis included patients who were ... Cited by 10 - Related articles - All 35 versions
AI Sebba, RD Emkey, JD Kohles, PN … - Bone, 2009 - Elsevier Note to users: The section "Articles in Press" contains peer reviewed accepted
articles to be published in this journal. When the final article is assigned to
an issue of the journal, the "Article in Press" version will be removed ... Cited by 6 - Related articles - All 23 versions
JR Curtis, AO Westfall, H Cheng, KG Saag, E … - Osteoporosis International, 2009 - Springer Abstract Summary The comparative effectiveness of alendronate and risedronate
has received limited evaluation. Among 19,063 new users of bisphosphonates,
risedronate users had a higher relative rate of hip fracture compared to ... Cited by 7 - Related articles - All 2 versions
AC Feldstein, D Weycker, GA Nichols, G … - Bone, 2009 - Elsevier This retrospective cohort study used a matched design that compared time to
clinical fracture in at-risk community women who initiated a bisphosphonate
medication between 7/1/1996 and 6/30/2006 to those who did not. The study ... Cited by 3 - Related articles - All 29 versions
[CITATION] Clinician's Guide to Prevention and Treatment of Osteoporosis
B Dawson-Hughes, R Lindsay, S Khosla… - National Osteoporosis Foundation, Washington DC, 2008 Cited by 4 - Related articles
NB WATTS, K WORLEY, AMY SOLIS, J … - JMCP, 2004 - amcp.org FORMULARY MANAGEMENT Comparison of Risedronate to Alendronate and Calcitonin for
Early Reduction of Nonvertebral Fracture Risk: Results From a Managed Care
Administrative Claims Database NELSON B. WATTS, MD; KAREN WORLEY, PhD; AMY ... Cited by 32 - Related articles - View as HTML - BL Direct - All 6 versions
J Payer, Z Killinger, I Šulková, P Celec - Biomedicine & Pharmacotherapy, 2007 - Elsevier Osteoporosis as a chronic disorder with relatively long asymptomatic initial
course represents a major problem. In addition, the currently available
therapeutic regimes are discomfortable and, thus, contribute to the low ... Cited by 5 - Related articles - All 3 versions
- ►mt.gov [PDF] PD Miller, S Epstein, F Sedarati, JY Reginster - Current Medical Research and Opinion®, 2007 - informahealthcare.com Objective: Oral ibandronate 150mg is the first bisphosphonate approved for
once-monthly treatment of postmenopausal osteoporosis. To investigate whether
once- monthly ibandronate 150mg increases lumbar spine and total hip bone ... Cited by 26 - Related articles - BL Direct - All 9 versions
KE Ensrud, JL Stock, E Barrett-Connor, D … - Journal of Bone and Mineral Research, 2008 - Am Soc Bone Min Res Dr Ensrud received research grant support through contracts with the University
of Minnesota from Eli Lilly and Company, Pfizer, Merck, Roche, Berlex, and
Bionovo. Dr Stock is a full-time employee of Eli Lilly and Company. Dr ... Cited by 8 - Related articles - All 6 versions
